Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer

Breast Cancer

Volumn 10, Issue 1, 2003, Pages 21-27

  Koizumi, Mitsuru ^a   Takahashi, Shunji ^b   Ogata, Etsuro ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b Cancer Institute Hospital   (Japan)

Author keywords

Bisphosphonate; Bone metabolic marker; Skeletal metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; TUMOR MARKER;

BONE DEVELOPMENT; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; METASTASIS; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOGENESIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041308329     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967621     Document Type: Review

References (45)

1. Abrams HL, Spiro R, Goldstein N: Metastases in carcinomas: analysis of 1000 autopsied cases. Cancer 3:74-85, 1950.
2. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Hefferman M, Reitsma DJ: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. New EnglJ Med 335:1785-1791, 1996. (Pubitemid 26412396)
3. Lipton A: Bisphosphonates and breast cancer. Cancer 80:1668-1673, 1997.
4. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New EnglJMed 339:357-363, 1998. (Pubitemid 28363797)
5. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al: Long term prevention of skeletal complication of metastatic breast cancer with pamidronate.J Clin Oncol 16:2038-2044, 1998. (Pubitemid 28265038)
6. Berenson JB, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. A double-blind, randomized dose-response study. Cancer 91:1191-1200, 2001. (Pubitemid 32267028)
7. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al: American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391, 2000. (Pubitemid 30159858)
8. Koizumi M: Bone scinfigraphy in oncology. Endo K ed, Mediculture, Tokyo, 2000 (in Japanese).
9. Yamamoto I: Skeletal nuclear medicine. Kakuigaku 32:523-529, 1995 (in Japanese with English abstract).
10. Krasnow AZ, Hellman RS, Timins M, Collier BD, Anderson T, Isitman AT: Diagnostic bone scanning in oncology. Semin Nucl Med 27:107-141, 1997. (Pubitemid 27194758)
11. Algra PR, Bloem JL, Tissing H, Falke THM, Arndt JW, Verboom LJ: Detection of vertebral metastases: comparison between MR imaging and bone scinfigraphy. Radiographics 11:219-232, 1991.
12. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA: Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.J Clin Oncol 13:1123-1128, 1995.
13. Pollen JF, Witztum KF, Ashburn WL: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roent 142:773-776, 1984. (Pubitemid 14166610)
14. Calvo MS, Eyre DR, Gundberg: Molecular basis and clinical application of biological markers of bone turnover. Endocrine Reviews 17:333-368, 1996. (Pubitemid 26277979)
15. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen K: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345, 2000. (Pubitemid 30413866)
16. Hiraga T, Tanaka S, Ikegame M, Koizumi M, Iguchi H, Nakajima T, Ozawa H: Morphology of bone metastasis. Eur J Cancer 34:230-239, 1998. (Pubitemid 28189191)
17. Delaisse JM, Eeckhout Y, Vaes G: In vivo and in vitro evidence for the involvement of cystein proteases in bone resorption. Biochem Biophys Res Commun 125:441-447, 1984. (Pubitemid 15155722)
18. Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M: Molecular cloning of a possible cysteine protease predominantly expressed in osteoclasts. J Biol Chem 269:1106-1109, 1994. (Pubitemid 24032492)
19. Nishi Y, Atley L, Eyre DE, Edelson JG, Superti-Furga A, Yasuda T, Desnick RJ, Gelb B: Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J Bone Miner Res 14:1902-1908, 1999. (Pubitemid 29521785)
20. Atley LM, Mort JS, Lalumiere M, Eyre DR: Proteolysis of human collagen by cathepsin K: characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26:241-247, 2000. (Pubitemid 30101647)
21. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, Risteli J: Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenecity by treatment with cathepsin K. Bone 26:367-373, 2000. (Pubitemid 30136127)
22. Karsda MA, Garnero P, Ferreras M, Risteli J, Ovist P, Foged N, Delaisse JM: Type I collagen fragments ICTP and CTx reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 16 (suppl): 195, 2001.
23. Stein GS, Lian JB, Owen TA: Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEBJ 4:3111-3123, 1990.
24. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonario J, Goldstein S, Gundberg C, Bradley A, Karsenty G: Increased bone formation in osteocalcin-deflcient mice. Nature 382:448-452, 1996. (Pubitemid 26264860)
25. Diel IJ, Solomayer EF, Siebel MJ, Pfeilschifter J, Maisenbacher H, Gollan C, Pecherstofer M, Conradi R, Kehr G, Boehm E, Armbruster FP, Bastert G: Serum sialoprotein in patients with primary breast cancer is prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914-3919, 1999. (Pubitemid 30013765)
26. Vinholes J, Coleman R, Eastell R: Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22:289-331, 1996. (Pubitemid 27075583)
27. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, Yamashita T, Maeda H, Takahashi S, Aiba K, Ogata E: Bone metabolic markers in bone metastasis. J Cancer Res Clin Oncol 121:542-548, 1995.
28. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A: Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 41:1489-1494, 1995.
29. Yamamoto I, Morita R, Konishi J, Shigeno C, Ikekubo K, Hino M, Sone T, Fujimoto R: Clinical studies using measurement of N-telopeptides of type-I collagen (NTx) in patients with bone metastasis. Kakuigaku 32:501-510, 1995.
30. Koizumi M, Takahashi S, Ogata E: Bone metabolic marker in bone metastasis of breast cancer. IntJ Clin Oncol 4:241-246, 1999.
31. Garnero P, Shin WJ, Gineyts E, Karpf DB, Dermas PD: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700, 1994.
32. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289-1294, 1997.
33. Coleman RE: Monitoring of bone metastases. Eur J Cancer 34:252-259, 1998. (Pubitemid 28189194)
34. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast cancer. Br J Cancer 73:1074-1079, 1996. (Pubitemid 26131227)
35. Koizumi M, Matsumoto S, Takahashi S, Yamashita T, Ogata E: Bone metabolic markers are useful in the diagnosis of bone scan flare phenomenon in bone metastases from breast cancers. Clin Nucl Med 24:15-20, 1999. (Pubitemid 29024655)
36. Body JJ, Coleman RE, Piccart M: Use of bisphosphohates in cancer patients. Cancer Treat Rev 22:265-287, 1996.
37. Kanis JA, Powels T, Paterson AH, McCloskey EV, Ashley S: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-667, 1996. (Pubitemid 27035848)
38. Saarto T, Blomquvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node positive breast cancer patients: 5-year results of randomized controlled trial. J Clin Onco119:10-17, 2001. (Pubitemid 32063474)
39. Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF, Ford J: Preliminary results of the use of urinary excretion of pyridium crosslinks for monitoring metastatic bone disease. Br J Cancer 65:766-768, 1992.
40. Garnero P,Gineyts E, Arbault P, Christiansen C, Dermas PD: Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone and Mineral Res 10:641-649, 1995.
41. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE: Metabolic effects of pamidronate in patients with metastatic bone disease. BrJ Cancer 73:1089-1095, 1996. (Pubitemid 26131230)
42. Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C: Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591-598, 1992.
43. Koizumi M, Setdne H, Aoki M, Hayashi S, Yamashita T, Oyamada H, Ogata E: Efficacy of YM-175, a new bisphosphonate, in the treatment of metastatic bone tumor from breast cancer and its effect on scintigraphy. Int J Clin Oncol 1:18-22, 1996. (Pubitemid 126721255)
44. Koizumi M, Kobayashi M, Furukawa M, Yamashita T, Ogata E: The bisphosphonate incadronate for bone metastases of breast cancer. Int J Clin Oncol 5:241-246, 2000.
45. Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, von Teichert JM: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91:144-154, 2001. (Pubitemid 32052625)